Back to Search

A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Mipasetamab Uzoptirine (ADCT-601) Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With Selected Advanced Solid Tumors

  • Protocol Number: 202205109
  • Principal Investigator: Van Tine, Brian
  • Cancer Types: Early Phase

For more information on this trial, contact us here:

[email protected]

Brief Summary

Protocol Interventions